Fragrance brands are experimenting with food-inspired scents as GLP-1 drugs change how users relate to appetite and smell, Telegraph India reports.
Recap by typeshit. Full story at Telegraph India.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
The review says incretin drugs can reduce sleep apnea severity in adults with obesity, alongside weight loss and some heart and metabolic gains.
Loading…